5326372026-01-012026-03-315326372026-03-315326372025-03-315326372025-04-012026-03-315326372026-01-012026-03-31in-capmkt:OtherExpenses1Member5326372025-04-012026-03-31in-capmkt:OtherExpenses1Member5326372026-03-31OtherNoncurrentFinancialAssetsDomain15326372026-03-31OtherNoncurrentAssetsDomain15326372026-03-31OtherCurrentFinancialAssetsDomain15326372026-03-31OtherCurrentAssetsDomain15326372026-03-31OtherNoncurrentFinancialLiabilitiesDomain15326372026-03-31OtherNoncurrentLiabilitiesDomain15326372026-03-31OtherCurrentFinancialLiabilitiesDomain15326372026-03-31OtherCurrentLiabilitiesDomain15326372026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares532637MANGALAMNOTLISTEDINE584F01014MANGALAM DRUGS AND ORGANICS LIMITEDMain BoardEquity2025-04-012026-03-312026-05-142026-05-06INRLakhsQuarterlyFourth quarterSingle segmentBulk manufacturing of Drugs2026-05-1412:30:002026-05-1416:00:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated6728710008940006737650003551080000116517000848740003082500046578000172577000806479000-1327140000-13271400026000146000014860000-1342000000000-134200000-1924000-136124000000015828200010-8.48-8.4800-8.48-8.481. The audited consolidated financial results of Mangalam Drugs and Organics Limited ( ‘’the Company or the Parent Company and its subsidiary referred as the ‘’Group’’) for the quarter and year ended March 31, 2026 have been prepared in accordance with Indian Accounting Standard (Ind AS) as prescribed under section 133 of the Companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter. <BR> 2. The figures for the last quarter are the balancing figures between audited figures in respect of full financial year upto March 31, 2026/ March 31, 2025 and the unaudited published year- to-date figures upto December 31, 2025/ December 31, 2024 being the date of the end of the third quarter of the financial year respectively which were subject to limited review. <BR> 3.The above audited consolidated financial results of the Group for the quarter and year ended March 31, 2026 have been reviewed by the Audit Committee and thereafter, approved by the Board of Directors at their meeting held on Thursday, May 14th, 2026. <BR> 4.The Group has business activity falls within a single reportable Business Segment Viz. “Manufacturing of Bulk Drugs”. <BR> 5. The Consolidated results includes results of Mangalam Laboratories Private Limited (MLPL) ,Wholly-owned subsidiary of the Company for the purpose of Consolidated results and it is not a material subsidiary of the Company. <BR> 6.The Board of Directors of the Company at its meeting held on March 15, 2024 had considered and approved the scheme of Merger by Absorption of its Wholly-owned Subsidiary ("First Transferor Company") and Shri JB Pharma Private Limited (Formerly known as Shri JB Pharma LLP) ("Second Transferor Company") with Parent Company ("Transferee Company") and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. The Scheme is subject to approval of Hon’ble National Company Law Tribunal. The hearing for the same is scheduled to be held on 02nd June, 2026. <BR> 7. On November 21, 2025, the Government of India notified the four Labour Codes consolidating 29 existing Labour laws. The Ministry of Labour & Employment has also issued draft Central Rules and FAQs to help assess the financial impact of these changes.Based on management assessment and the best information available, and in line with the guidance issued by the Institute of Chartered Accountants of India ("ICAI"), the incremental impact of these changes are not material to the standalone audited financial results of the Company for the quarter and year ended March 31, 2026. <BR> The Company continues to monitor the finalisation of Central and State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect subsequently on the basis of such developments as needed. <BR> 8. The figures for the previous periods / years have been regrouped whenever necessary to confirm to the current periods / years under presentation.2025-04-012026-03-31AuditedConsolidated232132700076310002328958000124792200003208350003378750001620840001822310005637250002814672000-4857140000-4857140002906000-44620000-417140000-4440000000000-444000000-4524000-448524000000015828200010872308000-28.05-28.0500-28.05-28.05Other Expenses172577000Other Expenses5637250001156840000000394043000388060000044000000440000284500015925780001027736000040297100070100000504000316890004421740000872050001557115000003149693000158282000872308000103059000001030590000856390000005000856440000520120000156430001532990009691880001210740006380680007591420007270300018010330001511250001364600019658040000021191030003149693000Other non-current financial assets0Other non-current assets2845000Other current financial assets31689000Other current assets87205000Other non-current financial liabilities5000Other non-current liabilities15643000Other current financial liabilities72703000Other current liabilities151125000162084000360282000-1224200006600300016622000000-222594000074135000-271440001822310000-65730000-31185000-144970000400000000-10676000-60450000530397000446830000002907000041776000000000001740000118993000000000000000000004000000-117249000000000000-218678000001620840000056594000-188790000-188790002588900070100001924000452400000-1924000-4524000AuditedtrueM/s. V. S. Somani & Co.true2027-07-31